Page last updated: 2024-09-04

febuxostat and hki 272

febuxostat has been researched along with hki 272 in 1 studies

Compound Research Comparison

Studies
(febuxostat)
Trials
(febuxostat)
Recent Studies (post-2010)
(febuxostat)
Studies
(hki 272)
Trials
(hki 272)
Recent Studies (post-2010) (hki 272)
81813371028342248

Protein Interaction Comparison

ProteinTaxonomyfebuxostat (IC50)hki 272 (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0416
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0298
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.8582
Serine/threonine-protein kinase Nek2Homo sapiens (human)0.274

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1

Other Studies

1 other study(ies) available for febuxostat and hki 272

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013